Cipher Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CPHRF research report →
About the company
Cipher Pharmaceuticals Inc. functions as a specialized pharmaceutical company based in Canada. The firm markets a diverse portfolio of therapies, including Epuris (CIP-ISOTRETINOIN), an isotretinoin formulation specifically developed for addressing severe acne; Ozenoxacin, prescribed for the management of impetigo in both adult and pediatric populations; Actikerall, indicated for treating palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream designed to diminish unwanted facial hair growth in women; BRINAVESS, a treatment aimed at restoring sinus rhythm in adults; and AGGRASTAT, an anti-platelet medication administered intravenously.
- CEO
- Craig J. Mull
- IPO
- 2006
- Employees
- 6
- HQ
- Mississauga, ON, CA
Price Chart
- Market Cap
- $298.86M
- P/E
- 9.91
- P/S
- 6.03
- P/B
- 2.30
- EV/EBITDA
- 11.98
- Div Yield
- 0.00%
- Gross Margin
- 74.53%
- Op Margin
- 38.76%
- Net Margin
- 60.82%
- ROE
- 25.69%
- ROIC
- 14.81%
- Revenue
- $51.33M · 53.87%
- Net Income
- $27.81M · 140.86%
- EPS
- $1.09 · 131.91%
- Op Income
- $16.80M
- FCF YoY
- 54.95%
- 52W High
- $15.00
- 52W Low
- $8.64
- 50D MA
- $12.36
- 200D MA
- $11.43
- Beta
- 0.48
- Avg Volume
- 3.72K
Get TickerSpark's AI analysis on CPHRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CPHRF coverage
Recent articles, reports, and earnings notes.
No research on CPHRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CPHRF report →Similar companies
Peers in the same neighborhood.